Información de la revista
Vol. 100. Núm. S2.
Mirando hacia el futuro en Dermatología Extraordinario del Centenario. Parte II
Páginas 22-27 (diciembre 2009)
Compartir
Compartir
Descargar PDF
Spanish PDF
Más opciones de artículo
Vol. 100. Núm. S2.
Mirando hacia el futuro en Dermatología Extraordinario del Centenario. Parte II
Páginas 22-27 (diciembre 2009)
Acceso a texto completo
Managing Comorbidities in Psoriasis
Tratamiento de enfermedades concomitantes en la psoriasis
Visitas
4721
W.H. Boehnckea,
Autor para correspondencia
Boehncke@em.uni-frankfurt.de

Correspondence: Department of Dermatology. Theodor-Stern-Kai 7. D – 60590 Frankfurt.
, S. Boehnckeb
a Department of Dermatology. Clinic of the Johann Wolfgang Goethe-University. Frankfurt am Main. Germany
b Department of Internal Medicine. Section of Endocrinology, Diabetes and Metabolism. Clinic of the Johann Wolfgang Goethe-University. Frankfurt am Main. Germany
Este artículo ha recibido
Información del artículo
Abstract

Psoriasis is a common inflammatory skin condition, often associated with other diseases. Around 25% of patients develop joint involvement in the form of psoriatic arthritis as well. Recent epidemiologic studies demonstrated an increased cardiovascular morbidity among psoriasis patients, which contributes to their reduced life expectancy. High prevalence of the metabolic syndrome as well as adverse effects of systemic anti-psoriatic therapies may contribute to the observed association. The consequences for the management of psoriasis at this point are three-fold: As comorbidity goes along with comedication, potential drug interactions need to be kept in mind when choosing a systemic anti-psoriatic therapy. Moreover, as psoriasis itself is a risk factor for cardiovascular morbidity, patients must avoid other known risk factors such as obesity or smoking. Dermatologists need to communicate this additional risk to their patients and support them accordingly. Finally, dermatologists serve as sentinels when it comes to the early diagnosis of developing comorbidities in general and psoriatic arthritis in particular, thus opening the door to early intervention.

Key words:
psoriasis
comorbidities
cardiovascular morbidity
Resumen

La psoriasis es una enfermedad inflamatoria cutánea frecuente, que se asocia a menudo con otros procesos. Aproximadamente el 25% de los pacientes desarrolla afectación articular en forma de artritis psoriásica. Estudios epidemiológicos recientes demuestran un aumento de la morbilidad cardiovascular en los pacientes con psoriasis, lo que contribuye a su menor esperanza de vida. La elevada prevalencia del síndrome metabólico, así como los efectos adversos de las terapias sistémicas para la psoriasis, pueden contribuir a la asociación observada. Las consecuencias para el tratamiento de la psoriasis son triples: hay que tener en cuenta las potenciales interacciones farmacológicas a la hora de elegir una terapia sistémica, ya que la patología asociada requiere medicación concomitante; además, como la psoriasis es un factor de riesgo en sí misma para la morbilidad cardiovascular, los pacientes deben evitar otros factores de riesgo conocidos como la obesidad o el tabaquismo. Los dermatólogos deben informar sobre este riesgo añadido y apoyar a sus pacientes. Por último, los dermatólogos sirven como centinelas cuando se trata de realizar un diagnóstico precoz de las enfermedades concomitantes en general y de la artritis psoriásica en particular, facilitando un tratamiento precoz.

Palabras clave:
psoriasis
enfermedades concomitantes
morbilidad cardiovascular
El Texto completo está disponible en PDF
References
[1.]
M.P. Schön, W.-H. Boehncke.
Psoriasis.
New Engl J Med, 352 (2005), pp. 1899-1912
[2.]
R. Sabat, S. Philipp, C. Höflich, S. Kreutzer, E. Wallace, K. Asadullah, et al.
Immunopathogenesis of psoriasis.
Exp Dermatol, 16 (2007), pp. 779-798
[3.]
K. Asadullah, H.-D. Volk, W. Sterry.
Novel immunotherapies for psoriasis.
Trends Immunol, 23 (2002), pp. 47-53
[4.]
W.-H. Boehncke.
Immunomodulatory drugs for psoriasis.
Br Med J, 327 (2003), pp. 634-635
[5.]
H. Maradit-Kremers, P.J. Nicola, C.S. Crowson, K.V. Ballman, S.E. Gabriel.
Cardiovascular death in rheumatoid arthritis: a population-based study.
Arthritis Rheum, 52 (2005), pp. 722-732
[6.]
C. Popa, M.G. Netea, T. Radstake, J.W. van der Meer, A.F. Stalenhoef, P.L. van Riel, et al.
Influence of anti-tumor necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
Ann Rheum Dis, 64 (2005), pp. 303-305
[7.]
D.L. Mattey, J.R. Glossop, N.B. Nixon, P.T. Dawes.
Circulating levels of tumor necrosis factor receptors are highly predictive of mortality in patients with rheumatoid arthritis.
Arthr Rheum, 56 (2007), pp. 3940-3948
[8.]
W.G. Dixon, K.D. Watson, M. Lunt, K.L. Hyrich.
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor a therapy.
Arthr Rheum, 56 (2007), pp. 2905-2912
[9.]
A.B. Gottlieb, C. Chao, F. Dann.
Psoriasis comorbidities.
J Dermatol Treat, 19 (2008), pp. 5-21
[10.]
D.D. Gladman, C. Antoni, P. Mease, D.O. Clegg, P. Nash.
Psoriatic arthritis: epidemiology, clinical features, course, and outcome.
Ann Rheum Dis, 64 (2005), pp. ii14-ii17
[11.]
D.D. Gladman, V.T. Farewell, C. Nadeau.
Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model.
J Rheumatol, 22 (1995), pp. 675-679
[12.]
E.R. Soriano, N.J. McHugh.
Therapies for peripheral joint disease in psoriatic arthritis. A systematic review.
J Rheumatol, 33 (2006), pp. 1422-1430
[13.]
W. Taylor, D. Gladman, P. Helliwell, A. Marchesoni, P. Mease, H. Mielants, On behalf of the CASPAR Study Group.
Classification criteria for psoriatic arthritis: development of new criteria from a large international study.
Arthr Rheum, 54 (2006), pp. 2665-2673
[14.]
T. Henseler, E. Christophers.
Disease concomitance in psoriasis.
J Am Acad Dermatol, 32 (1995), pp. 982-986
[15.]
J.M. Gelfand, A.B. Troxel, J.D. Lewis, S.K. Kurd, D.B. Shin, X. Wang, et al.
The risk of mortality in patients with psoriasis: results from a population-based study.
Arch Dermatol, 143 (2007), pp. 1493-1499
[16.]
L. Mallbris, O. Akre, F. Granath, L. Yin, B. Lindelöf, A. Ekbom, et al.
Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients.
Eur J Epidemiol, 19 (2004), pp. 225-230
[17.]
J.M. Gelfand, A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, A.B. Troxel.
Risk of myocardial infarction in patients with psoriasis.
JAMA, 296 (2006), pp. 1735-1741
[18.]
R.J. Ludwig, C. Herzog, A. Rostock, F.R. Ochsendorf, T.M. Zollner, D. Thaci, et al.
Psoriasis: a possible risk factor for development of coronary artery calcification.
Br J Dermatol, 156 (2007), pp. 271-276
[19.]
W.H. Boehncke, C. Bürger, S. Boehncke.
Co-morbidities in psoriasis vulgaris.
Hautarzt, 60 (2009), pp. 116-121
[20.]
S. Boehncke, D. Thaci, H. Beschmann, R.J. Ludwig, H. Ackermann, K. Badenhoop, et al.
Psoriasis patients show signs of insulin resistance.
Br J Dermatol, 157 (2007), pp. 1249-1251
[21.]
L. Naldi, L. Chatenoud, D. Linder, A. Belloni Fortina, A. Peserico, A.R. Virgili, et al.
Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study.
J Invest Dermatol, 125 (2005), pp. 61-67
[22.]
A. Nast, I. Kopp, M. Augustin, K.B. Banditt, W.-H. Boehncke, M. Follmann, et al.
German evidence-based guidelines for the treatment of psoriasis vulgaris.
Arch Dermatol Res, 299 (2007), pp. 111-138
[23.]
S. Gerdes, V.A. Zahl, H. Knopf, M. Weichenthal, U. Mrowietz.
Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis.
Br J Dermatol, 159 (2008), pp. 1116-1123
[24.]
A.B. Kimball, D.D. Gladman, J.M. Gelfand, K. Gordon, E.J. Horn, N.J. Korman, et al.
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.
J Am Acad Dermatol, 58 (2008), pp. 1031-1042
Copyright © 2009. Academia Española de Dermatología y Venereología
Descargar PDF
Idiomas
Actas Dermo-Sifiliográficas
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?